Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies-Reference-Cited by-同舟云学术

Clinical Efficacy of Imdevimab/Casirivimab for Persistent Omicron SARS-CoV-2 Infection in Patients with Hematological Malignancies

Published:2024-08-15 Issue:16 Volume:63 Page:2283-2287
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Hagihara Masao¹,Hayashi Hiroyoshi¹,Nakashima Shiori¹,Imai Yui¹,Nakano Hirofumi¹,Uchida Tomoyuki¹,Inoue Morihiro¹,Sakai-Tagawa Yuko²,Ito Mutsumi²,Yamayoshi Seiya²³,Iwatsuki-Horimoto Kiyoko²,Suzuki Yutaka⁴,Kawaoka Yoshihiro²³⁵⁶

Affiliation:

1. Department of Hematology, Eiju General Hospital, Japan

2. Division of Virology, Institute of Medical Science, The University of Tokyo, Japan

3. The Research Center for Global Viral Disease, Research Institute, National Center for Global Health and Medicine, Japan

4. Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Japan

5. Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Japan

6. Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, USA

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/63/16/63_2900-23/_pdf

Reference23 articles.

1. 1. Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv 4: 5966-5975, 2020.

2. 2. Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 7: e737-e745, 2020.

3. 3. Ohara S, Fujii T, Ide S, Uchida T, Inoue M, Hagaihara M. Clinical characteristics and risk factors associated with nosocomial COVID-19 infection in patients with hematological disorders in Japan. Int J Hematol 114: 719-724, 2021.

4. 4. Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br J Haematol 195: 371-377, 2021.

5. 5. Narita K, Nakaji S, Tabata R, et al. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol 115: 728-736, 2022.